This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Bharat Biotech expects to share further details of the trial results as additional data become available.
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Subscribe To Our Newsletter & Stay Updated
